How health technology reassessment can support disinvestment in China’s national drug reimbursement list Post date 15 June 2023 ← Use of real world data to improve drug coverage decisions in China → Using health technology assessment to inform insurance reimbursement of high technology medicines in China: an example of cancer immunotherapy